Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS

Plain-language summary

This study examines how often variants in the GBA and PSAP genes occur in patients diagnosed with multiple myeloma (a type of bone marrow cancer) or MGUS. Adults with one of these two diagnoses who provide consent can take part. It is a study without an assigned phase and is still enrolling participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

University Hospital, Rouen

Intervention

Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS

Start date

10/7/2025

Estimated completion

4/1/2027

Countries

France

Related genes

Locations

• Rouen, France
• Rouen, France

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Major patients with multiple myeloma (MM) (defined by clonal proliferation of tumour plasma cells (\>10%), presence of a monoclonal peak in serum or urine (excluding non-secretory myeloma) and organ involvement secondary to bone marrow invasion) or with MGUS (defined as bone marrow plasmacytosis of less than 10%, associated with a monoclonal protein of less than 30g/L and no clinical involvement).
* Membership of a social security scheme
* Adult having read and understood the information letter and signed the consent form

Exclusion Criteria:

* Person deprived of liberty by an administrative or judicial decision or person placed under court protection / sub-guardianship or guardianship